Dare Bioscience, Inc. · NASDAQ:DARE
Dare Bioscience — Investor Presentation (June 2019)
14 slides from Dare Bioscience's investor presentation, Jun 3, 2019
Slide 1: Accelerating innovation by daring to be different
Exhibit 99.1 Accelerating innovation by daring to be different June 3, 2019
Slide 2: Forward Looking Statements
Forward Looking Statements THIS PRESENTATION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES OF DARÉ BIOSCIENCE, INC. (“DARÉ” OR THE “COMPANY”). THIS PRESENTATION INCLUDES CERTAIN INFORMATION OBTAINED FROM TRADE AND STATISTICAL SERVI
Slide 3: Vision and Mission
Vision: To become the premier innovation accelerator in women’s health. Mission: We achieve this by identifying, unlocking and advancing candidates with potential to be first-in-category, address persistent unmet needs, and promote a better quality of life for women. 3
Slide 4: Daring to be different
Daring to be different • A pure play biopharmaceutical company focused on improving the health and well being of women. Our focus areas include: • Contraception / Pregnancy Prevention • Sexual Health • Vaginal Health • Fertility • Partnering is core to our licensing and value creation strategy: • Pr
Slide 5: Pipeline
Regulatory aa ” a > ie ae DARE-BV1" Phase 3 Initiation 4Q 2019 potential Firstine Option for BV Ovaprene® (PCT)’..... Top line 2H 2019 __First-in-category Non-Hormonal, Monthly Contraception Sildenafil Cream, 3.6% Top line 4Q 2020 First-in-category for Treatment of Female Sexual Arousal Disorder een
Slide 6: DARE-BV1 Clindamycin 2% gel for Bacterial Vaginosis
DARE-BV1 Clindamycin 2% gel for Bacterial Vaginosis
Slide 7: DARE-BV1 Overview
DARE-BV1 Overview Bacterial Vaginosis (BV) Successful Proof of Concept • Vaginal application of DARE-BV1 (clindamycin phosphate 2%) demonstrated effectiveness against BV in a proof-of-concept investigator initiated study in women (n=30):1 • 86% of evaluable subjects met clinical cure endpoint at Tes
Slide 8: Contraception Expected to be a $33 billion global category by 2023
Contraception Expected to be a $33 billion global category by 20231 1. Global Market Insights, https://globenewswire.com/news-release/2016/05/19/841462/0/en/Contraceptives-Market-size-to-exceed-33-Billion-by-2023-Global-Market-Insights-Inc.html
Slide 9: Ovaprene Overview
Ovaprene ® Overview New Contraceptive Option Successful Proof of Concept Study • Ovaprene demonstrated effectiveness in preventing sperm from entering the cervical canal in a proof-of-concept study in women (n=20):1 • No viable sperm in the cervical mucus • No colposcopic abnormalities CDRH (Device)
Slide 10: Women's Sexual Health & Wellness
Women’s Sexual Health & Wellness Female Sexual Arousal Disorder (FSAD) World market for both male and female sexual dysfunction drugs will reach 7.7 billion in 20191 1. https://www.visiongain.com/sexual-dysfunction-drugs-market-will-reach-7-7bn-in-2019-predicts-a-new-visiongain-study/
Slide 11: Female Sexual Arousal Disorder (FSAD) Sildenafil Cream, 3.6%
Female Sexual Arousal Disorder (FSAD) Sildenafil Cream, 3.6% Successful Proof of Concept • Sildenafil Cream, 3.6% improved genital blood flow in a proof-of-concept study (n=31):1 • Efficacy signal observed in both pre and postmenopausal patients • Excellent systemic/local safety and tolerability pro
Slide 12: Female Sexual Arousal Disorder (FSAD) Sildenafil Cream, 3.6%
Female Sexual Arousal Disorder (FSAD) Sildenafil Cream, 3.6% Hypoactive Sexual Female Sexual Vulvar-Vaginal Dyspareunia Desire Disorder Arousal Disorder Atrophy (HSDD) (FSAD) No Approved Products With its approval of Addyi®, FDA has now acknowledged and formally classified the distinct and separate
Slide 13: Portfolio Timeline Overview
Portfolio Timeline Overview 2019 2020 2021 2022 2023 2024 Current Development Status DARE-BV1^ U.S. Potential U.S. (Bacterial Vaginosis) Phase 3 Program Regulatory Review Launch U.S. Potential U.S. Ovaprene® Pivotal Regulatory Review Launch (Contraception) PCT* Study CDRH / Device Lead Sildenafil Cr
Slide 14: Corporate & Investor Communications
Corporate & Investor Communications NASDAQ: DARE Trading as DARE since July 20, 2017 www.darebioscience.com 14